An Open Label, Phase II Trial of Afatinib With or Without Vinorelbine for the Treatment of HER2-overexpressing Inflammatory Breast Cancer
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003635/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, locally advanced or metastatic inflammatory breast cancer. The study will include patients who have and have not failed prior trastuzumab treatment.
提供机构：
Vivli
创建时间：
2019-04-12
